Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
NCT07920211, Phase 2, Phase 3, Not yet recruiting, Teva Branded Pharmaceutical Products R&D LLC
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo | ClinicalTrials.gov |
| NCT number | NCT07920211 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2, Phase 3 | ClinicalTrials.gov |
| Enrollment | 1,020 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D LLC | ClinicalTrials.gov |
| Conditions | Vitiligo | ClinicalTrials.gov |
| Interventions | TEV-53408 Dose A, TEV-53408 Dose B, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Trial 1: Proportion of Participants Achieving a ≥75% Reduction in Facial Vitiligo Area Scoring Index (F-VASI75) | Baseline, Week 24 | The F-VASI assesses the percentage of facial area affected by vitiligo. It ranges from 0 to 3.5, with 0 representing no vitiligo on the face and 3.5 representing complete depigmentation of the assessed facial areas. | ClinicalTrials.gov |
| Primary | Trial 2: Proportion of Participants Achieving F-VASI75 | Baseline, Week 48 | ClinicalTrials.gov | |
| Primary | Trial 2: Proportion of Participants Achieving T-VASI50 (US Only) | Baseline, Week 48 | T-VASI is the sum for all body sites of the product of percentage of BSA affected multiplied by the degree of depigmentation. T-VASI ranges from 0 to 100, with 0 representing no vitiligo and 100 representing complete depigmentation of the entire body. | ClinicalTrials.gov |
| Secondary | Trial 1: Proportion of Participants Achieving a ≥50% Reduction in Facial Vitiligo Area Scoring Index (F-VASI50) | Baseline, Week 24 | ClinicalTrials.gov | |
| Secondary | Trial 1: Proportion of Participants Achieving F-VASI75 | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Proportion of Participants Achieving a ≥50% Reduction in Total Vitiligo Area Scoring Index (T-VASI50) | Baseline, Week 24 | ClinicalTrials.gov | |
| Secondary | Trial 1: Proportion of Participants Achieving T-VASI50 | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Percent Change in Facial Vitiligo Area Scoring Index (F-VASI) | Baseline, Week 24 | ClinicalTrials.gov | |
| Secondary | Trial 1: Percent Change in F-VASI | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Percent Change in Total Vitiligo Area Scoring Index (T-VASI) | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Proportion of Participants Achieving a Vitiligo Noticeability Scale (VNS) score of "A lot less noticeable (4)" or "No longer noticeable (5)" | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Proportion of Participants Achieving (1) "Very much improved" or (2) "Much improved" on Patient Global Impression of Change -Vitiligo (PaGIC-V) | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 1: Incidence of Treatment-Emergent Adverse Events (TEAEs) | Week 88 | ClinicalTrials.gov | |
| Secondary | Trial 1: Incidence of Serious Adverse Events (SAEs) | Week 88 | ClinicalTrials.gov | |
| Secondary | Trial 1: Incidence of Adverse Events (AEs) Leading to Discontinuation | Week 88 | ClinicalTrials.gov | |
| Secondary | Trial 1: Incidence of Protocol-Defined AEs of Special Interest (PDAESIs) | Week 88 | ClinicalTrials.gov | |
| Secondary | Trial 2: Proportion of Participants Achieving T-VASI50 (non-US only) | Baseline, Week 48 | ClinicalTrials.gov | |
| Secondary | Trial 2: Proportion of Participants Achieving F-VASI75 | Baseline, Week 24 | ClinicalTrials.gov | |
| Secondary | Trial 2: Percent Change in Facial Vitiligo Area Scoring Index (F-VASI) | Baseline, Week 24 | ClinicalTrials.gov | |
| Secondary | Trial 2: Proportion of Participants Achieving F-VASI50 | Baseline, Week 48 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)